Candel Therapeutics plans BLA submission by year-end for aglatimogen in prostate cancer
Candel Therapeutics said a pivotal phase III trial for aglatimogen in prostate cancer met its primary endpoint, supporting a planned BLA submission by year-end. The company expects new biomarker and long-term survivor data in Q3 and Q4.
A pivotal phase III trial of aglatimogen in prostate cancer met its primary endpoint, supporting a planned BLA submission by year-end. Manufacturing and regulatory work remains on schedule, and the company expects new biomarker data in Q3 and long-term survivor data in Q4.